Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes

Table 2 Baseline characteristics, clinical presentation, with different controlled glycemia

Characteristic	≤6.5%	Between 6.5% and 7%	>7%	P
Number	16	39	15
age(yr)	58.31 ± 7.21	59.30 ± 6.87	57.33 ± 8.23	0.652
Duration of diabetes(yr)	7.84 ± 1.02	8.01 ± 0.97	13.96 ± 1.35	0.012^#
Baseline BMI(kg/m²)	24.11 ± 3.34	24.87 ± 3.56	23.98 ± 4.56	0.143
Baseline weight (kg)	61.35 ± 8.76	60.04 ± 9.13	58.23 ± 3.58	0.087
Baseline WHR	0.89 ± 0.09	0.90 ± 0.12	0.86 ± 0.15	0.321
Baseline HbA1c(%)	7.25 ± 1.02	8.11 ± 0.85	9.32 ± 1.23	0.028^#
Baseline fasting C-peptide	1.82 ± 0.65	1.87 ± 0.78	1.84 ± 0.53	0.083
Baseline 2-h postprandial C-peptide	4.83 ± 2.11	3.89 ± 1.15	2.54 ± 0.87	0.034^#
Baseline premixed insulin dose(U/d)	30.50 ± 4.12	30.23 ± 7.65	33.87 ± 8.21	0.056
HbA1c change from baseline	0.82 ± 0.10	1.42 ± 0.33	1.62 ± 0.58	0.008*
Concomitant OADs during the study n (%)
Metformin	4(5.71)	8(11.43)	0(0.00)
SUs	7(10.00)	18(25.71)	3(4.29)
α-glucosidase	5(7.14)	11(15.71)	2(2.86)
Met/SUs	0(0.00)	2(2.86)	6(8.57)
Met/α-glucosidase	0(0.00)	0(0.00)	2(2.86)
SUs/α-glucosidase	0(0.00)	0(0.00)	2(2.86)

ISSN: 1758-5996